Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03336333 · OUTCOME

Cohort 1: Overall Survival (OS) Between Treatment Groups as Determined by the ICR

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL · Source last updated 2026-03-09

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 5 years

What was measured

OS in Cohort 1 is defined as the time from randomization to the date of death due to any reason.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
anticipated Posting Date
2027-09
denom Units Selected
Participants
description
OS in Cohort 1 is defined as the time from randomization to the date of death due to any reason.
reporting Status
NOT_POSTED
time Frame
Up to 5 years
title
Cohort 1: Overall Survival (OS) Between Treatment Groups as Determined by the ICR
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice